BB&T Corp cut its position in Medidata Solutions, Inc. (NASDAQ:MDSO) by 0.7% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,735 shares of the company’s stock after selling 40 shares during the period. BB&T Corp’s holdings in Medidata Solutions were worth $448,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the company. Airain ltd acquired a new stake in shares of Medidata Solutions during the first quarter worth $439,000. AQR Capital Management LLC acquired a new stake in shares of Medidata Solutions during the fourth quarter worth $703,000. BNP Paribas Arbitrage SA boosted its stake in shares of Medidata Solutions by 9.8% in the first quarter. BNP Paribas Arbitrage SA now owns 11,171 shares of the company’s stock worth $644,000 after buying an additional 997 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Medidata Solutions during the fourth quarter worth $2,975,000. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Medidata Solutions by 1.8% in the first quarter. Parametric Portfolio Associates LLC now owns 91,576 shares of the company’s stock worth $5,283,000 after buying an additional 1,618 shares during the period.
Shares of Medidata Solutions, Inc. (NASDAQ MDSO) traded down 0.34% on Friday, hitting $72.28. 186,291 shares of the stock traded hands. The stock’s 50 day moving average price is $77.43 and its 200 day moving average price is $66.95. The stock has a market cap of $4.09 billion, a P/E ratio of 116.77 and a beta of 1.79. Medidata Solutions, Inc. has a 52-week low of $46.10 and a 52-week high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The firm had revenue of $137.41 million for the quarter, compared to the consensus estimate of $134.28 million. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The company’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 EPS. On average, equities analysts expect that Medidata Solutions, Inc. will post $1.28 EPS for the current fiscal year.
WARNING: This article was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/08/18/bbt-corp-sells-40-shares-of-medidata-solutions-inc-mdso-updated-updated.html.
MDSO has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Friday, July 21st. SunTrust Banks, Inc. upped their price objective on shares of Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. Morgan Stanley upped their price objective on shares of Medidata Solutions from $74.00 to $86.00 and gave the stock an “overweight” rating in a report on Thursday, July 20th. Citigroup Inc. restated a “buy” rating and issued a $95.00 price objective (up previously from $94.00) on shares of Medidata Solutions in a report on Monday, July 24th. Finally, J P Morgan Chase & Co upped their price objective on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $78.17.
In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total transaction of $372,650.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Taylor sold 5,639 shares of Medidata Solutions stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $73.46, for a total transaction of $414,240.94. Following the sale, the director now owns 54,372 shares of the company’s stock, valued at $3,994,167.12. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by insiders.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
What are top analysts saying about Medidata Solutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Medidata Solutions Inc. and related companies.